Innoviva, Inc. (INVA)
23.00
+0.46
(+2.04%)
USD |
NASDAQ |
Jun 10, 16:00
23.02
+0.02
(+0.07%)
After-Hours: 20:00
Innoviva EPS Diluted (Quarterly) : 2.216 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 2.216 |
| December 31, 2025 | 1.944 |
| September 30, 2025 | 1.082 |
| June 30, 2025 | 0.7727 |
| March 31, 2025 | -0.7429 |
| December 31, 2024 | 0.2827 |
| September 30, 2024 | 0.0193 |
| June 30, 2024 | -0.5547 |
| March 31, 2024 | 0.462 |
| December 31, 2023 | 0.7613 |
| September 30, 2023 | 0.9845 |
| June 30, 2023 | 0.0196 |
| March 31, 2023 | 0.4185 |
| December 31, 2022 | -0.9807 |
| September 30, 2022 | 2.804 |
| June 30, 2022 | 0.0135 |
| March 31, 2022 | 0.1957 |
| December 31, 2021 | 0.1265 |
| September 30, 2021 | 0.9012 |
| June 30, 2021 | 0.8954 |
| March 31, 2021 | 0.839 |
| December 31, 2020 | 0.485 |
| September 30, 2020 | 0.2588 |
| June 30, 2020 | 0.6872 |
| March 31, 2020 | 0.5869 |
| Date | Value |
|---|---|
| December 31, 2019 | 0.4153 |
| September 30, 2019 | 0.3612 |
| June 30, 2019 | 0.343 |
| March 31, 2019 | 0.3105 |
| December 31, 2018 | 2.340 |
| September 30, 2018 | 0.43 |
| June 30, 2018 | 0.49 |
| March 31, 2018 | 0.27 |
| December 31, 2017 | 0.50 |
| September 30, 2017 | 0.21 |
| June 30, 2017 | 0.30 |
| March 31, 2017 | 0.15 |
| December 31, 2016 | 0.2601 |
| September 30, 2016 | 0.13 |
| June 30, 2016 | 0.13 |
| March 31, 2016 | 0.04 |
| December 31, 2015 | 0.04 |
| September 30, 2015 | -0.04 |
| June 30, 2015 | -0.07 |
| March 31, 2015 | -0.09 |
| December 31, 2014 | -0.14 |
| September 30, 2014 | -0.19 |
| June 30, 2014 | -0.57 |
| March 31, 2014 | -0.62 |
| December 31, 2013 | -0.46 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 1.276 |
| Corcept Therapeutics, Inc. | -0.2988 |
| Assertio Holdings, Inc. | -2.931 |
| Veru, Inc. | -0.1342 |
| Johnson & Johnson | 2.141 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 186.60M |
| Revenue (Quarterly) | 101.45M |
| Total Expenses (Quarterly) | -85.14M |
| Enterprise Value | 1.417B |
| Gross Profit Margin (Quarterly) | 74.75% |
| Earnings Yield | 26.15% |
| Operating Earnings Yield | 8.22% |
| Normalized Earnings Yield | 10.69 |